I would hope so. PR about agreements and potential revenue streams are great and the fact they seem to be moving forward a good sign but at the same time it would be interesting to read how these FDA issues will be dealt with. I mean some of the issues seem rather basic in simple implementatin of process controls which any new company would have to do with a new medical technology. The real issue is addressing the definition of minimal manipulation. Maybe its as simple as stating in process terms that water is the only outside component used. I mean unless they state the process how would anyone know.